Find clinical trials for Adenocarcinoma in Valencia, VC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Pancreatic Cancer

Stomach Cancer

Non-Small-Cell Lung Carcinoma

Colorectal Cancer

Prostatic Cancer

Esophageal Cancer

Cancer

Adenocarcinoma trials near Valencia, VC, ESP:

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regim...

Active, not recruiting

Gastric Cancer, Adenocarcinoma

Gastroesophageal Junction Adenocarcinoma

Drug: Ramucirumab

Drug: Paclitaxel

Phase 3

Daiichi Sankyo

Valencia, Spain and 155 other locations

TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma

new standard backbone in patients with resectable esophagogastric adenocarcinoma. It addresses major limitations of current treatment paradi...

Begins enrollment in 1 month

Esophagogastric Adenocarcinoma

Drug: Durvalumab

Phase 2

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Valencia, Spain and 28 other locations

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

(CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...

Enrolling

Gastroesophageal Junction Adenocarcinoma

Esophageal Cancer

Drug: Sonesitatug vedotin

Drug: Nivolumab

Phase 3

AstraZeneca

Valencia, Spain and 257 other locations

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA)

participants to treat locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEA).T...

Enrolling

Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma

Esophageal Adenocarcinoma

Drug: Budigalimab

Drug: Oxaliplatin

Phase 2

AbbVie

Valencia, Spain and 48 other locations

Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma (PANSOTO)

objective of this trial is to evaluate the safety and tolerability of sotorasib combined with first-line chemotherapy for advanced pancreatic adenocarcinoma...

Enrolling

Pancreatic Adenocarcinoma

Drug: Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)

Phase 1

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Valencia, Valencia, Spain and 26 other locations

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease....

Enrolling

Gastroesophageal Adenocarcinoma

Drug: 5-Fluorouracil (5-FU)

Drug: Capecitabine

Phase 2

AstraZeneca

Valencia, Spain and 69 other locations

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 302)

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.

Active, not recruiting

PDAC - Pancreatic Ductal Adenocarcinoma

PDAC

Drug: 5-fluorouracil

Drug: leucovorin

Phase 3

Revolution Medicines

Valencia, Spain and 59 other locations

Locations recently updated

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

with chemotherapy in participants with previously untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma...

Enrolling

Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Drug: Nivolumab

Drug: Pumitamig

Phase 2, Phase 3

Bristol-Myers Squibb (BMS)

Valencia, Valenciana, Comunitat, Spain and 160 other locations

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection comp...

Enrolling

Metastatic Gastric Adenocarcinoma

Gastroesophageal Junction Adenocarcinoma

Drug: 5-fluorouracil (5-FU)

Drug: Cisplatin

Phase 3

BeOne Medicines

Valencia, Spain and 84 other locations

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

with chemotherapy in treating adults with Claudin 18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma...

Active, not recruiting

Metastatic Gastric Adenocarcinoma or Cancer

Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer

Drug: placebo

Drug: zolbetuximab

Phase 3

Astellas

Valencia, Spain and 164 other locations

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms

Find clinical trials for Adenocarcinoma in .css-epvm6{white-space:nowrap;}Valencia, VC

Related conditions:

Adenocarcinoma trials near Valencia, VC, ESP:

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma (PANSOTO)

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 302)

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

Find clinical trials for Adenocarcinoma in Valencia, VC